Researchers have reported a small-molecule inhibitor of Candida albican protein Bdf1 and demonstrated the compound yields decreased fungal viability, suggesting a possible future antifungal.
Browsing: Fungal > Candidiasis
Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery (CO-ADD) discusses his work towards uncovering compounds with antibiotic potential and shares his thoughts on the best strategies to tackle antibiotic resistance moving forwards.
Even in the era of antiretroviral treatment, mucosal candidiasis remains one of the most common manifestations in HIV-infected subjects. This editorial discusses the loss of immune control that allows mucosal candidiasis to occur.